Retrieve available abstracts of 43 articles: HTML format
Single Articles
June 2025
LI Y, Wu Z, Ma J, Liu X, et al Zinc Attenuates Prostate Hyperplasia and Inflammatory Injury in Obese Rats by
Regulating Zinc Homeostasis and Inhibiting the JAK1/STAT3 Pathway.
Prostate. 2025;85:767-776. PubMedAbstract available
SUN A, Rodriguez-Alvarez JS, Harper S, Khooblall P, et al The Prostate Microbiome Is Associated With Prostate Size and PSA Level,
Independent of Age, in BPH Patients.
Prostate. 2025;85:850-859. PubMedAbstract available
April 2025
PAE S, Sakamoto S, Zhao X, Tamura T, et al LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate
Cancer Patients After Radiotherapy.
Prostate. 2025 Apr 2. doi: 10.1002/pros.24899. PubMedAbstract available
March 2025
GUERRA LHA, da Costa Castro NF, Jubilato FC, Marques LA, et al Coconut Oil Mitigates the Effects of Aging on the Mongolian Gerbil Prostate.
Prostate. 2025;85:395-406. PubMedAbstract available
February 2025
RINGLER R, Gangwish D, Horning P, Kuperus J, et al Does size matter? A single institution's comparison of Aquablation in prostates
greater than or less than 150 mL.
Prostate. 2025;85:140-147. PubMedAbstract available
ABDELAZIZ AY, Kishk MA, Meshref A, Elfayomy H, et al Safety and Efficacy of Intra-Prostatic Injection of Betamethasone for Refractory
Chronic Nonbacterial Prostatitis: A Prospective Cohort Clinical Study.
Prostate. 2025;85:243-251. PubMedAbstract available
December 2024
KONG X, Dong Z, Hu W, Mi J, et al The role of gut microbiota involved in prostate microenvironment and symptoms
improvement in chronic prostatitis/chronic pelvic pain syndrome patients treated
with low-intensity extracorporeal shock wave.
Prostate. 2024;84:1525-1536. PubMedAbstract available
ALVES BB, Gabrich P, Favorito LA Prospective results of the minimally invasive laser enucleation of the prostate
(MiLEP).
Prostate. 2024;84:1501-1505. PubMedAbstract available
November 2024
WARREN CJ, Payne NG, Edmonds VS, Voleti SS, et al Quality of Chatbot Information Related to Benign Prostatic Hyperplasia.
Prostate. 2024 Nov 8. doi: 10.1002/pros.24814. PubMedAbstract available
September 2024
JIRASKO M, Vitak R, Pecen L, Pinkeova A, et al Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio,
Prostate Health Index, and glycosylation patterns of free PSA in patients with
benign prostatic hyperplasia pharmacotherapy.
Prostate. 2024 Sep 27. doi: 10.1002/pros.24801. PubMedAbstract available
ZHANG P, Wang H, Li P, Fu X, et al Assessing state-of-the-art online large language models for patient education
regarding prostatitis.
Prostate. 2024;84:1173-1175. PubMed
August 2024
IGARASHI T, Mizoguchi S, Matsuoka K, Kamijo T, et al Effects of oral administration of nonselective Trk inhibitor on bladder
overactivity in rodent models of prostatic inflammation.
Prostate. 2024;84:1016-1024. PubMedAbstract available
July 2024
LIU TT, Igarashi T, El-Khoury N, Ihejirika N, et al Benign prostatic hyperplasia nodules in patients treated with celecoxib and/or
finasteride have reduced levels of NADH dehydrogenase [ubiquinone] iron-sulfur
protein 3, a mitochondrial protein essential for efficient function of the
electron transport
Prostate. 2024 Jul 14. doi: 10.1002/pros.24766. PubMedAbstract available
May 2024
ZHANG Y, Zhou J Responses to queries concerning "Performance of large language models on benign
prostatic hyperplasia frequently asked questions".
Prostate. 2024 May 16. doi: 10.1002/pros.24748. PubMed
DAUNGSUPAWONG H, Wiwanitkit V Large language models and benign prostatic hyperplasia frequently asked
questions.
Prostate. 2024 May 16. doi: 10.1002/pros.24719. PubMed
HUA X, Zhang J, Chen J, Feng R, et al Sodium butyrate alleviates experimental autoimmune prostatitis by inhibiting
oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO-1 pathway.
Prostate. 2024;84:666-681. PubMedAbstract available
April 2024
ABID A, Piperdi H, Babar M, Loloi J, et al Minimally invasive surgical therapies for benign prostatic hyperplasia in the
geriatric population: A systematic review.
Prostate. 2024 Apr 24. doi: 10.1002/pros.24717. PubMedAbstract available
ROPER C, Slade A, Caras R, Shelton T, et al Ejaculatory and erectile function outcomes following holmium laser enucleation of
the prostate.
Prostate. 2024 Apr 1. doi: 10.1002/pros.24697. PubMedAbstract available
ZHANG Y, Dong Y, Mei Z, Hou Y, et al Performance of large language models on benign prostatic hyperplasia frequently
asked questions.
Prostate. 2024 Apr 1. doi: 10.1002/pros.24699. PubMedAbstract available
March 2024
ZHAO X, Feng R, Chen J, Jiang Q, et al 4-Octyl itaconate alleviates experimental autoimmune prostatitis by inhibiting
the NLRP3 inflammasome-induced pyroptosis through activating Nrf2/HO-1 pathway.
Prostate. 2024;84:329-341. PubMedAbstract available
February 2024
KAMADA S, Sakamoto S, Kinoshita R, Zhao X, et al Testosterone bounce predicts favorable prognoses for prostate cancer patients
treated with degarelix.
Prostate. 2024 Feb 27. doi: 10.1002/pros.24679. PubMedAbstract available
SHIBAMORI K, Kyoda Y, Shindo T, Hashimoto K, et al Maternal diet during gestation affect prostatic tissue component in SHR/Izm
offspring.
Prostate. 2024;84:303-314. PubMedAbstract available
January 2024
CAVANAUGH D, Urbanucci A, Mohamed NE, Tewari AK, et al Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower
urinary tract symptoms (LUTS).
Prostate. 2024 Jan 9. doi: 10.1002/pros.24656. PubMedAbstract available
WHITE JA, Kaninjing ET, Adeniji KA, Jibrin P, et al Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased
alterations in apoptotic pathways.
Prostate. 2024 Jan 8. doi: 10.1002/pros.24662. PubMedAbstract available
JIN R, Forbes CM, Miller NL, Lafin J, et al Transcriptomic analysis of benign prostatic hyperplasia identifies critical
pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
Prostate. 2024 Jan 3. doi: 10.1002/pros.24661. PubMedAbstract available
December 2023
LEE KS, Yoo JW, Kim DH, Jeon S, et al A prospective, randomized, open-label, parallel trial comparing the efficacy of
alpha-blocker or 5alpha-reductase inhibitor withdrawal to continued combination therapy
on the maintenance of lower urinary tract symptoms in men with benign prostatic
hyp
Prostate. 2023 Dec 27. doi: 10.1002/pros.24663. PubMedAbstract available
SCHNEIDER AJ, Serrell EC, Grimes M, Wang S, et al Histologic inflammation and collagen content are not positively correlated in
human BPH.
Prostate. 2023;83:1529-1536. PubMedAbstract available
November 2023
MARIOTTI ACH, Heidrich V, Inoue LT, Coser EM, et al Urinary microbiota is associated to clinicopathological features in benign
prostatic hyperplasia.
Prostate. 2023 Nov 13. doi: 10.1002/pros.24649. PubMedAbstract available
October 2023
DI H, Wen Y Vasectomy and risk of prostate cancer: A Mendelian randomization study and
confounder analysis.
Prostate. 2023 Oct 31. doi: 10.1002/pros.24646. PubMedAbstract available
ZHOU H, Xu M, Pan Y, Wang S, et al The association between several serum micronutrients and benign prostatic
hyperplasia: Results from NHANES 2003-2006.
Prostate. 2023 Oct 29. doi: 10.1002/pros.24641. PubMedAbstract available
HATA J, Matsuoka K, Akaihata H, Meguro S, et al The activated complement pathway in the fibrous process of benign prostatic
hyperplasia.
Prostate. 2023 Oct 25. doi: 10.1002/pros.24639. PubMedAbstract available
ZHANG Y, Peng R, Chen Z, Zhang W, et al Evidence for a causal effect of major depressive disorder, anxiety on prostatitis
risk: A univariate and multivariate Mendelian randomization study.
Prostate. 2023;83:1387-1392. PubMedAbstract available
WESTHOFEN T, Bensel M, Schlenker B, Becker A, et al The impact of previous inguinal mesh hernioplasty on oncological and
patient-reported outcomes following radical prostatectomy.
Prostate. 2023;83:1313-1322. PubMedAbstract available
September 2023
FUJIWARA S, Kosaka T, Nishimoto Y, Kamisawa K, et al Prognostic significance of serum testosterone level in patients with
castration-resistant prostate cancer treated with cabazitaxel.
Prostate. 2023 Sep 3. doi: 10.1002/pros.24620. PubMedAbstract available
July 2023
LV K, Yang G, Wu Y, Xia X, et al The causal effect of metabolic syndrome and its components on benign prostatic
hyperplasia: A univariable and multivariable Mendelian randomization study.
Prostate. 2023 Jul 16. doi: 10.1002/pros.24598. PubMedAbstract available
June 2023
SEVIM M, Alkis O, Kartal IG, Kazan HO, et al Comparison of transcutaneous tibial nerve stimulation versus percutaneous tibial
nerve stimulation in category IIIB chronic prostatitis/chronic pelvic pain
syndrome: A randomized prospective trial.
Prostate. 2023;83:751-758. PubMedAbstract available
LI Z, Lao Y, Bai Y, Li W, et al Re: Comparison of transcutaneous tibial nerve stimulation versus percutaneous
tibial nerve stimulation in category IIIB chronic prostatitis/chronic pelvic pain
syndrome: A randomized prospective trial.
Prostate. 2023;83:896-897. PubMed
LEBANI BR, Barcelos ADS, Gouveia DSES, Girotti ME, et al The role of transurethral resection of prostate (TURP) in patients with
underactive bladder: 12 months follow-up in different grades of detrusor
contractility.
Prostate. 2023;83:857-862. PubMedAbstract available
May 2023
LEE S, Yoo KH, Kim TS, Cho HJ, et al Characteristics of recurrent acute urinary retention in BPH patients in the
United States: Retrospective analysis of US-based insurance claims database.
Prostate. 2023;83:722-728. PubMedAbstract available
BABAR M, Loloi J, Tang K, Singh S, et al Rezum water vapor therapy for patients with mild, moderate, or severe lower
urinary tract symptoms: A retrospective study in a multiethnic population.
Prostate. 2023;83:713-721. PubMedAbstract available
April 2023
BENGTSEN MB, Heide-Jorgensen U, Borre M, Norgaard M, et al Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary
retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker
monotherapy in routine clinical care.
Prostate. 2023 Apr 14. doi: 10.1002/pros.24540. PubMedAbstract available
March 2023
MIYAZAWA Y, Nakamura T, Takezawa Y, Shimizu N, et al A prospective study of the relationship between CRPC patient's quality of life
after enzalutamide and serum testosterone levels measured via LC-MS/MS.
Prostate. 2023 Mar 9. doi: 10.1002/pros.24514. PubMedAbstract available
February 2023
BECK J, Rouleau M, Lemire F, Neveu B, et al Mass spectrometry redefines optimal testosterone thresholds in prostate cancer
patients undergoing androgen deprivation therapy.
Prostate. 2023 Feb 27. doi: 10.1002/pros.24501. PubMedAbstract available